OracleBio will be attending the 2nd Global NASH Congress 2019, which takes place from the 25th to 26th of February in London, UK.
OracleBio will be exhibiting at Booth #1 and presenting a poster in Position #25 at the conference.
OracleBio is a leading digital pathology service provider with in-depth expertise in supporting NASH/NAFLD & Fibrosis research. Utilising Visiopharm Oncotopix and Indica Labs Halo image analysis software, we provide detailed quantification of cells and biomarkers in liver tissue including immune/inflammatory cell count, collagen levels, vacuole content and fibrotic lesion area in stained histology / IHC tissue slides. We deliver cell-by-cell data for improved study interpretation and decision making in preclinical and clinical R&D. Click here to find out more information about how our services can support your NASH research.
The 2nd Global NASH Congress program covers the latest research and development in pathogenesis, diagnosis, and treatment of the disease. The congress will focus on promising developments in research that will hopefully bolster drug development and other methods of treatment. In addition, it will examine exciting advancements in non-invasive diagnostic biomarkers, in vivo liver models, and a better understanding of the disease’s mechanisms, as well as on the challenges of preclinical and clinical research in NASH. To find out more about the 2nd Global NASH Congress 2019, please click here.
John Waller, OracleBio’s COO, along with our Business Development Manager, Hannah Thomson, and Business Development Assistant, Alison Stewart, will be at Booth #1 throughout the congress.
If you would like to learn more about OracleBio’s services, or wish to arrange a time to speak with our team during the event, please contact us.